[go: up one dir, main page]

WO2007065036A3 - Therapeutic conjugates and methods of using same - Google Patents

Therapeutic conjugates and methods of using same Download PDF

Info

Publication number
WO2007065036A3
WO2007065036A3 PCT/US2006/046459 US2006046459W WO2007065036A3 WO 2007065036 A3 WO2007065036 A3 WO 2007065036A3 US 2006046459 W US2006046459 W US 2006046459W WO 2007065036 A3 WO2007065036 A3 WO 2007065036A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
same
compositions
therapeutic conjugates
gabapentin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/046459
Other languages
French (fr)
Other versions
WO2007065036A2 (en
Inventor
Timothy J Fultz
Yuqiang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adamas Pharmaceuticals Inc
Original Assignee
Neuromolecular Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuromolecular Pharmaceuticals Inc filed Critical Neuromolecular Pharmaceuticals Inc
Publication of WO2007065036A2 publication Critical patent/WO2007065036A2/en
Anticipated expiration legal-status Critical
Publication of WO2007065036A3 publication Critical patent/WO2007065036A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel gabapentin-aminoadamantane derivative combinations (e.g. gabapentin-memantine) combinatorial compositions, methods of making the compositions, and methods for the treatment and prevention of neurological diseases, e.g., epilepsy, and neuropathic and chronic pain, using the compositions of the invention.
PCT/US2006/046459 2005-12-02 2006-12-04 Therapeutic conjugates and methods of using same Ceased WO2007065036A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74196205P 2005-12-02 2005-12-02
US60/741,962 2005-12-02

Publications (2)

Publication Number Publication Date
WO2007065036A2 WO2007065036A2 (en) 2007-06-07
WO2007065036A3 true WO2007065036A3 (en) 2008-07-31

Family

ID=37806190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046459 Ceased WO2007065036A2 (en) 2005-12-02 2006-12-04 Therapeutic conjugates and methods of using same

Country Status (1)

Country Link
WO (1) WO2007065036A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507648A (en) 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド Novel psychotropic drug with glutamic acid NMDA activity
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2010048423A1 (en) 2008-10-24 2010-04-29 Ark Diagnostics, Inc. Levetiracetam immunoassays
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
US9920136B2 (en) 2013-02-13 2018-03-20 Ark Diagnostics, Inc. Posaconazole immunoassays
CN118290279A (en) * 2014-05-29 2024-07-05 广州喜鹊医药有限公司 Salts of amantadine nitrate compounds with neuroprotective effect
US11447442B2 (en) 2017-11-22 2022-09-20 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat CNS disorders
CN119215024A (en) * 2024-09-29 2024-12-31 中国辐射防护研究院 Application of memantine, hydrogen-rich water and their combination in the preparation of drugs for treating radiation-induced brain injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142998A1 (en) * 2000-10-06 2002-10-03 Cundy Kenneth C. Bile-acid conjugates for providing sustained systemic concentrations of drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142998A1 (en) * 2000-10-06 2002-10-03 Cundy Kenneth C. Bile-acid conjugates for providing sustained systemic concentrations of drugs

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BRYANS ET AL: "Identification of novel ligands for the Gabapentin binding site", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 41, 1 January 1998 (1998-01-01), pages 183818 - 45, XP002139354, ISSN: 0022-2623 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHI, WEI-GUO ET AL: "Design and synthesis of mutual prodrugs for relieving neuropathic pain (II)", XP002482875, retrieved from STN Database accession no. 2007:1408625 *
HONG-JU Y ET AL: "Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 10, 17 May 2004 (2004-05-17), pages 2537 - 2541, XP004841234, ISSN: 0960-894X *
OTAGIRI M ET AL: "Improving the pharmacokinetic and pharmacodynamic properties of a drug by chemical conversion to a chimera drug", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 62, no. 1-2, 1 November 1999 (1999-11-01), pages 223 - 229, XP004363020, ISSN: 0168-3659 *
SHARMA V ET AL: "Prodrugs and mutual prodrugs: Synthesis of some new pyrazolone and oxadiazole analogues of a few non-steroidal anti-inflammatory drugs", PHARMAZIE 20030201 DE, vol. 58, no. 2, 1 February 2003 (2003-02-01), pages 99 - 103, XP008092471, ISSN: 0031-7144 *
SHI W ET AL: "DESIGN, SYNTHESIS, AND PRELIMINARY EVALUATION OF GABAPENTIN-PREGABALIN MUTUAL PRODRUGS IN RELIEVING NEUROPATHIC PAIN", ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 338, no. 8, 1 January 2005 (2005-01-01), pages 358 - 364, XP008067446, ISSN: 0365-6233 *
YOON MYUNG HA ET AL: "Antinociceptive interactions between intrathecal gabapentin and MK801 or NBQX in rat formalin test", JOURNAL OF KOREAN MEDICAL SCIENCE, vol. 20, no. 2, April 2005 (2005-04-01), pages 307 - 312, XP002482874, ISSN: 1011-8934 *
ZHONGGUO XINYAO ZAZHI , 16(20), 1689-1692 CODEN: ZXZHA6; ISSN: 1003-3734, 2007 *
ZOIDIS G ET AL: "The novel GABA adamantane derivative (AdGABA): design, synthesis, and activity relationship with gabapentin", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 13, no. 8, 15 April 2005 (2005-04-15), pages 2791 - 2798, XP004802818, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
WO2007065036A2 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2005046603A3 (en) Pyridine compounds
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
WO2007022506A3 (en) Methods and compositions for treating neurological disease
WO2006124748A3 (en) Multicyclic compounds and methods of their use
ZA200802762B (en) Pharmaceutical compositions for the treatment of inner ear disorders
WO2007120729A3 (en) Pyridyl amide t-type calcium channel antagonists
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2006058867A3 (en) Substituted pteridines for the treatment of inflammatory diseases
WO2007009007A3 (en) Methods of treatment using hydroquinone ansamycins
WO2006058869A3 (en) Substituted pteridines for treating inflammatory diseases
WO2006131322A3 (en) Use op brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2007065036A3 (en) Therapeutic conjugates and methods of using same
WO2008125902A8 (en) Peripheral and neural inflammatory crosstalk
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2005092062A3 (en) Compounds for neurodegenerative disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06839047

Country of ref document: EP

Kind code of ref document: A2